Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
Cartesian Therapeutics, Inc. Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025 , expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the year ended December 31, 2025, and outlined recent business updates. “Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 a
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics (RNAC) had its "outperform" rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.MarketBeat
- Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by BTIG Research.MarketBeat
- Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
- Cartesian Therapeutics (RNAC) was upgraded by Cantor Fitzgerald from "neutral" to "overweight". They now have a $16.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
RNAC
Earnings
- 3/9/26 - Miss
RNAC
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form SCHEDULE
- 3/9/26 - Form 10-K
- RNAC's page on the SEC website